Pramoxine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
Overview
Pramoxine is a local anesthetic that is FDA approved for the treatment of for the temporary relief of itching associated with minor skin irritations. Common adverse reactions include contact dermatitis, eczema.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- For the temporary relief of itching associated with minor skin irritations
Dosing information
- To open, squeeze cap tightly and turn pump counter-clockwise.
- Adults and children 2 years of age and older:
- apply to affected area not more than 3 to 4 times daily.
- Children under 2 years of age: consult a doctor.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Pramoxine in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Pramoxine in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Pramoxine in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Pramoxine in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Pramoxine in pediatric patients.
Contraindications
There is limited information regarding Pramoxine Contraindications in the drug label.
Warnings
- For external use only
- When using this product
- avoid contact with the eyes.
- Stop use and ask a doctor if
- condition worsens
- symptoms persist for more than 7 days or clear up and occur again within a few days.
- Caution -- Do not use in the eyes or nose. Not for prolonged use. Do not apply to large areas of the body. If redness, irritation, swelling, or pain persists or increases, discontinue use unless directed by a physician.
- Keep out of reach of children.
- If swallowed, get medical help or contact a Poison Control Center right away.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Pramoxine in the drug label.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Pramoxine in the drug label.
Drug Interactions
There is limited information regarding Pramoxine Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): C
There is no FDA guidance on usage of Pramoxine in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pramoxine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Pramoxine during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Pramoxine with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Pramoxine with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Pramoxine with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Pramoxine with respect to specific gender populations.
Race
There is no FDA guidance on the use of Pramoxine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Pramoxine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Pramoxine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Pramoxine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Pramoxine in patients who are immunocompromised.
Administration and Monitoring
Administration
- Topical
Monitoring
There is limited information regarding Monitoring of Pramoxine in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Pramoxine in the drug label.
Overdosage
There is limited information regarding Chronic Overdose of Pramoxine in the drug label.
Pharmacology
Pramoxine
| |
Systematic (IUPAC) name | |
4-[3-(4-butoxyphenoxy)propyl]morpholine | |
Identifiers | |
CAS number | 637-58-1 |
ATC code | D04 C05AD07 (WHO) |
PubChem | |
Chemical data | |
Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
Mol. mass | 293.401 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Topical, rectal, Vaginal |
Mechanism of Action
There is limited information regarding Pramoxine Mechanism of Action in the drug label.
Structure
There is limited information regarding Pramoxine Structure in the drug label.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Pramoxine in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Pramoxine in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Pramoxine in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Pramoxine in the drug label.
How Supplied
There is limited information regarding Pramoxine How Supplied in the drug label.
Storage
There is limited information regarding Pramoxine Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Pramoxine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Pramoxine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Pramoxine in the drug label.
Precautions with Alcohol
- Alcohol-Pramoxine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Curasore
- Prax
- Proctofoam-NS
- Tronolane
- Sarna Sensitive
- Proctofoam
- PramoxGel
Look-Alike Drug Names
There is limited information regarding Pramoxine Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
{{#subobject:
|Label Page=Pramoxine |Label Name=Pramoxine03.png
}}
{{#subobject:
|Label Page=Pramoxine |Label Name=Pramoxine04.png
}}